Uncategorized Archives

New Study Reveals Breakthrough Triple-Combination Strategy to Strengthen Silver-Based Antimicrobials Against Hospital Infections

Vancouver, British Columbia — April 21, 2026 Andira Pharmaceuticals Inc., in collaboration with researchers at the University of British Columbia, today announced the publication of a new peer-reviewed study describing a novel antimicrobial strategy that dramatically enhances the effectiveness of silver against some of the most dangerous healthcare-associated pathogens, including

Andira Pharmaceuticals Advances First-In-Class Topical Therapy for Post-Mastectomy Pain Toward FDA IND Filing

FOR IMMEDIATE RELEASE November 25, 2025 A new topical treatment may reduce post-mastectomy pain and opioid use by activating the endocannabinoid system (ECS) Vancouver, BC, Canada — A new hope for breast cancer patients, Andira Pharmaceuticals today announced FDA filing plans for a new topical treatment, AND-254, aimed at reducing pain after mastectomy

Andira’s Silvanex™ Shows Zero MRSA Resistance Potential in Landmark AMR Study

FOR IMMEDIATE RELEASE Andira’s Silvanex™ Shows Zero MRSA Resistance Potential in Landmark AMR Study Vancouver, BC – July 22, 2025 — Andira Pharmaceuticals, a global leader in cannabinoid-based therapeutics, today announced breakthrough results from an independent antimicrobial resistance (AMR) study conducted by Element Materials Technology. The study found that Silvanex™

New Study Reveals Breakthrough Triple-Combination Strategy to Strengthen Silver-Based Antimicrobials Against Hospital Infections

Andira Pharmaceuticals Advances First-In-Class Topical Therapy for Post-Mastectomy Pain Toward FDA IND Filing

Andira’s Silvanex™ Shows Zero MRSA Resistance Potential in Landmark AMR Study

Explore

Contact Us

Investor Relations:

Partnerships:

General inquiries and media: